PBYI — PUMA BIOTECHNOLOGY, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401667 ·
Last close
$9.12
Market Cap
$470.77M
52W High
$9.51
52W Low
$6.78
ADV30
322,355
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 56,502,000 | 44,027,000 | 7,585,000 | 8,189,000 | 192,736,000 | 36,537,000 | 54,192,000 |
| Mar 2026 | 44,814,000 | 34,390,000 | -3,828,000 | -3,753,000 | 192,699,000 | 36,193,000 | 64,283,000 |
| Dec 2025 | 75,453,000 | 52,326,000 | 17,106,000 | 13,438,000 | 216,302,000 | 29,635,000 | 85,962,000 |
| Sep 2025 | 54,475,000 | 42,302,000 | 9,573,000 | 8,844,000 | 202,862,000 | 53,525,000 | 87,594,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$41,148,000
Investing CF
$-16,025,000
Financing CF
$-45,339,000
CapEx
$-123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.52
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,279,339,000
Inventory
$13,324,000
Receivables
$34,060,000
ST Investments
$57,366,000
EBIT TTM
$34,687,000
Pretax Income TTM
$31,168,000
Interest Exp TTM
$3,519,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$231,244,000
EBITDA
$40,115,000
Free Cash Flow
$32,473,124
Enterprise Value
$381,688,992
Total Cash
$93,903,000
Total Debt
$4,817,000
Shares Out
51,620,066
Trailing EPS
$0.51
Book Value
$2.71
ROE
22.0%
ROA
9.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 228,371,000 | 37,299,000 | 31,111,000 | 216,302,000 | 85,962,000 | — | 41,802,000 |
| Dec 2024 | 230,468,000 | 30,966,000 | 30,278,000 | 213,333,000 | 121,208,000 | — | 38,918,000 |
| Dec 2023 | 235,637,000 | 32,640,000 | 21,591,000 | 230,528,000 | 177,086,000 | — | 27,009,000 |
| Dec 2022 | 228,031,000 | 30,720,000 | 2,000 | 222,059,000 | 200,451,000 | — | -15,827,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Max Pain — expiry 2026-09-18
max pain strike: $5.00 · spot: $9.31 · call oi: 1,308 · put oi: 126
Expected Move to 2026-09-18:
±$0.98
(10.47%) —
implied range
$8.34 –
$10.29
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $481.01M | $7.28 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $482.05M | $9.39 | — |
| RZLT | Rezolute, Inc. | $482.42M | $5.01 | — |
| KMDA | KAMADA LTD | $486.36M | $8.43 | — |
| QTTB | Q32 Bio Inc. | $487.03M | $16.36 | — |
News headlines (Yahoo Finance, 1h cache)
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
2026-08-14 14:27 · Yahoo
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
2026-08-12 13:40 · Yahoo
Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...
2026-08-07 05:10 · Yahoo
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
2026-05-14 12:04 · Yahoo
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
2026-05-11 13:04 · Yahoo
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
2026-08-07 15:15 · Yahoo
Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary
2026-08-07 12:30 · Yahoo
Puma Biotechnology Reports Second Quarter 2026 Financial Results
2026-08-06 20:05 · Yahoo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-08-05 21:00 · Yahoo
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
2026-07-30 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.